Propylthiouracil (PTU) is the most common antithyroid medication utilized in children for the treatment of hyperthyroidism. An adverse effect of PTU reported infrequently is hepatic injury. The child described here is the fifth reported case of severe hepatic injury in the pediatric age group and documents that clinical or biochemical evidence of hepatic injury requires immediate discontinuation of PTU.
Get full access to this article
View all access options for this article.
References
1.
LevyWJSchumacherOPGuptaM. Treatment of childhood Graves' disease. A review with emphasis on radioiodine treatment. Cleve Clin J Med1988; 55: 373–82.
2.
GortonCSadeghi-NejadASeniorB. Remission in children with hyperthyroidism treated with propylthiouracil. Am J Dis Child1987: 141: 1084–6.
3.
LippeBMLandawEMKaplanSA. Hyperthyroidism in children treated with long term medical therapy: Twenty-five percent remission every two years. J Clin Endocrinol Metab1987; 64: 1241–5.
4.
OkamuraKIkenoueHShiroozuASatoKYoshinariMFujishimaM. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab1987; 65: 719–23.
5.
JonasMMEidsonMS. Propylthiouracil hepatotoxicity: Two pediatric cases and review of the literature. J Pediatr Gastroenterol Nutr1988; 7: 776–9.
6.
VitugACGoldmanJM. Hepatoxicity from antithyroid drugs. Horm Res1985; 21: 229–34.
